---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-081562"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:17:29.652652+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interim CFO Drexler resigns; Garner appointed PFO/PAO, will depart May 15, 2024

## Summary
- Susan L. Drexler resigned as Interim CFO, PFO and PAO effective March 25, 2024; remains consultant via Danforth Advisors.
- Charles Garner appointed as principal financial officer and principal accounting officer effective March 25, 2024.
- Garner's employment ends May 15, 2024; he will receive 12 months base salary severance if not terminated for cause or he quits without good reason before then.
- Garner previously SVP Finance since Oct 2023, former CFO of Lung Therapeutics (acquired by Aileron).
- No permanent CFO replacement announced; leadership transition in finance.

## SEC filing metadata
- accession: 0001193125-24-081562
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/d800276d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-081562
- JSON: https://secwatch.observer/filing/0001193125-24-081562.json
- Plain text: https://secwatch.observer/filing/0001193125-24-081562.txt

## Key facts
- Executive change
  Charles Garner was appointed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: the Board of Directors of the Company appointed Charles Garner to serve as the Company’s principal financial officer and principal accounting officer, effective as of March 25, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm
- Executive change
  Susan L. Drexler resigned as Interim Chief Financial Officer, principal financial officer and principal accounting officer at Rein Therapeutics, Inc..
  - Action: resigned
  - Role: Interim Chief Financial Officer, principal financial officer and principal accounting officer
  source text: On March 25, 2024, Susan L. Drexler, Interim Chief Financial Officer, principal financial officer and principal accounting officer of Aileron Therapeutics, Inc. (the “Company”), notified the Company of her resignation, effective as of March 25, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm
- Executive change
  Charles Garner departed as principal financial officer and principal accounting officer at Rein Therapeutics, Inc..
  - Action: agreed that his employment will end
  - Role: principal financial officer and principal accounting officer
  source text: Separately, the Company and Mr. Garner have agreed that his employment with the Company will end effective as of May 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524081562/0001193125-24-081562-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.